Abstract
The congenital CMV infection is the most common intrauterine transmitted viral infection. Since the first description in 1904 a lot of knowledge on epidemiology has been gained. Socio-economic maternal factors play a major role, and seem to be one of the major reasons for the differences of prevalence of congenital CMV infection between Europe and North America. Concerning the interaction of CMV and placental cells, reactions of the host immune system have a dual effect - protection against the virus on the one hand, and supporting of virus production and release of CMV on the other hand. In the last years new strategies for prevention and therapy of congenital CMV infection have been investigated. Passive immunization for prevention of transmission of the virus seems to be promising, but also therapy with ganciclovir of congenital infected newborns showed good results. Taking the side effects of antiviral therapy into consideration, active and passive immunization may ultimately be the best control strategy for this important public health problem.
Keywords: placental barrier, CMV genes, IL-8, immunization, fibroblasts
Current Pharmaceutical Biotechnology
Title: The Congenital Cytomegalovirus Infection: Virus-Host Interaction for Defense and Transmission
Volume: 7 Issue: 4
Author(s): Gabriele Halwachs-Baumann
Affiliation:
Keywords: placental barrier, CMV genes, IL-8, immunization, fibroblasts
Abstract: The congenital CMV infection is the most common intrauterine transmitted viral infection. Since the first description in 1904 a lot of knowledge on epidemiology has been gained. Socio-economic maternal factors play a major role, and seem to be one of the major reasons for the differences of prevalence of congenital CMV infection between Europe and North America. Concerning the interaction of CMV and placental cells, reactions of the host immune system have a dual effect - protection against the virus on the one hand, and supporting of virus production and release of CMV on the other hand. In the last years new strategies for prevention and therapy of congenital CMV infection have been investigated. Passive immunization for prevention of transmission of the virus seems to be promising, but also therapy with ganciclovir of congenital infected newborns showed good results. Taking the side effects of antiviral therapy into consideration, active and passive immunization may ultimately be the best control strategy for this important public health problem.
Export Options
About this article
Cite this article as:
Halwachs-Baumann Gabriele, The Congenital Cytomegalovirus Infection: Virus-Host Interaction for Defense and Transmission, Current Pharmaceutical Biotechnology 2006; 7 (4) . https://dx.doi.org/10.2174/138920106777950780
DOI https://dx.doi.org/10.2174/138920106777950780 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cadmium as an Endocrine Disruptor in the Reproductive System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Heat Shock Factor 1-Regulated miRNAs Can Target Huntingtin and Suppress Aggregates of Mutant Huntingtin
MicroRNA MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Prenatal Exposure of a Novel Antipsychotic Aripiprazole: Impact on Maternal, Fetal and Postnatal Body Weight Modulation in Rats
Current Drug Safety Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry The Ligand Binding Region of the Sigma-1 Receptor: Studies Utilizing Photoaffinity Probes, Sphingosine and N-Alkylamines
Current Pharmaceutical Design